Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rice Krispies immunity claims under fire

This article was originally published in The Tan Sheet

Executive Summary

The Kellogg Co. and the Oregon Department of Justice settle a case involving the marketer's claims that Rice Krispies cereal "helps support your child's immunity," the Oregon Attorney General John Kroger's office reports. The settlement requires Kellogg to stop shipping cereal boxes with the immunity language by Jan. 15, destroy more than 2 million units of packaging with the claim and cease making such claims unless it provides the Oregon Department of Justice with "advance notice and competent reliable scientific evidence." Additionally, the company agrees to donate nearly 500,000 boxes of cereal to organizations that feed the hungry. Kellogg made the immunity claim as part of a campaign for Rice Krispies, Cocoa Krispies, Frosted Krispies and MultiGrain Jumbo Krispies. FDA warned cereal maker General Mills over heart health claims made for Cheerios oat cereal in 2009 (1"The Tan Sheet" May 18, 2009)

You may also be interested in...



FDA Cheerios Warning Signals Tougher Stance On Health Claims Enforcement

FDA's warning letter to General Mills concerning cardiovascular health claims linked to Cheerios reflects a newly empowered agency and foreshadows aggressive regulatory activity to come, experts say

Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm

Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel